152 related articles for article (PubMed ID: 19422685)
1. Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice.
Yiang GT; Harn HJ; Yu YL; Hu SC; Hung YT; Hsieh CJ; Lin SZ; Wei CW
J Biomed Sci; 2009 May; 16(1):47. PubMed ID: 19422685
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice.
Yiang GT; Chou PL; Tsai HF; Chen LA; Chang WJ; Yu YL; Wei CW
Int J Mol Med; 2012 May; 29(5):809-14. PubMed ID: 22367420
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression.
Yu YL; Wei CW; Chen YL; Chen MH; Yiang GT
Int J Oncol; 2010 Feb; 36(2):365-70. PubMed ID: 20043070
[TBL] [Abstract][Full Text] [Related]
4. Long-term expression of rAAV2-hIL15 enhances immunoglobulin production and lymphokine-activated killer cell-mediated human glioblastoma cell death.
Yiang GT; Chou RH; Chang WJ; Wei CW; Yu YL
Mol Clin Oncol; 2013 Mar; 1(2):321-325. PubMed ID: 24649169
[TBL] [Abstract][Full Text] [Related]
5. Enriched Environment Cues Suggest a New Strategy to Counteract Glioma: Engineered rAAV2-IL-15 Microglia Modulate the Tumor Microenvironment.
Mormino A; Bernardini G; Cocozza G; Corbi N; Passananti C; Santoni A; Limatola C; Garofalo S
Front Immunol; 2021; 12():730128. PubMed ID: 34552593
[TBL] [Abstract][Full Text] [Related]
6. [Human endostatin antiangiogenic gene therapy mediated by recombinant adeno-associated virus vector in nude mouse with endometriosis].
Sun JJ; Yin LR; Mi RR; Ma HD; Guo SJ; Shi Y; Gu YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):45-50. PubMed ID: 20367926
[TBL] [Abstract][Full Text] [Related]
7. Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals.
Ru Q; Li W; Wang X; Zhang S; Chen L; Zhang Y; Ge Y; Zu Y; Liu Y; Zheng D
Cancer Gene Ther; 2017 Jun; 24(6):251-258. PubMed ID: 28429751
[TBL] [Abstract][Full Text] [Related]
8. AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells.
Chiu TL; Lin SZ; Hsieh WH; Peng CW
Int J Oncol; 2009 Dec; 35(6):1361-7. PubMed ID: 19885559
[TBL] [Abstract][Full Text] [Related]
9. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
10. [IL15 DNA adjuvant enhances cellular and humoral immune responses induced by DNA and adenoviral vectors encoding HIV-1 subtype B gp160 gene].
Xu K; Xu SH; Feng X; Yu SQ; Zeng Y
Bing Du Xue Bao; 2014 Jan; 30(1):62-5. PubMed ID: 24772900
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
12. Improvement of Photoreceptor Targeting via Intravitreal Delivery in Mouse and Human Retina Using Combinatory rAAV2 Capsid Mutant Vectors.
Reid CA; Ertel KJ; Lipinski DM
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6429-6439. PubMed ID: 29260200
[TBL] [Abstract][Full Text] [Related]
13. Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma.
Teschendorf C; Warrington KH; Shi W; Siemann DW; Muzyczka N
Anticancer Res; 2006; 26(1A):311-7. PubMed ID: 16475712
[TBL] [Abstract][Full Text] [Related]
14. The dual effect of ultrasound-targeted microbubble destruction in mediating recombinant adeno-associated virus delivery in renal cell carcinoma: transfection enhancement and tumor inhibition.
Li F; Jin L; Wang H; Wei F; Bai M; Shi Q; Du L
J Gene Med; 2014; 16(1-2):28-39. PubMed ID: 24464622
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cancer immunotherapy utilizing programmed Salmonella typhimurium secreting heterologous flagellin B conjugated to interleukin-15 proteins.
Zhang Y; Tan W; Sultonova RD; Nguyen DH; Zheng JH; You SH; Rhee JH; Kim SY; Khim K; Hong Y; Min JJ
Biomaterials; 2023 Jul; 298():122135. PubMed ID: 37148758
[TBL] [Abstract][Full Text] [Related]
16. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery.
Towne C; Pertin M; Beggah AT; Aebischer P; Decosterd I
Mol Pain; 2009 Sep; 5():52. PubMed ID: 19737386
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
18. rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion.
Ding W; Zhang LN; Yeaman C; Engelhardt JF
Mol Ther; 2006 Apr; 13(4):671-82. PubMed ID: 16442847
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of colon tumor growth by IL-15 immunogene therapy.
He X; Li W; Wang Y; Hou L; Zhu L
Mol Med Rep; 2012 Jan; 5(1):96-102. PubMed ID: 21956355
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma.
Hsu FT; Liu YC; Tsai CL; Yueh PF; Chang CH; Lan KL
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
